RAPA-501-Allo

RAPA-501-Allo is an investigational allogeneic cell therapy composed of T-cells extracted from healthy volunteers, which are reprogrammed ex vivo through a proprietary two-step process involving de-differentiation and re-differentiation. This process yields a hybrid TREG/Th2 phenotype with dual anti-inflammatory properties. The cells inhibit inflammatory pathways by modulating cytokines and chemokines, cross-regulating Th1 and Th17 populations, and suppressing effector T cell as well as CNS microglial inflammatory molecules. The immunomodulatory effects occur in a T-cell receptor independent manner. RAPA-501-Allo is being developed primarily for the treatment of COVID-19-related ARDS but shares mechanistic similarities with autologous versions under investigation for ALS[1][3][8].